Literature DB >> 22621641

BRAF inhibition in refractory hairy-cell leukemia.

Sascha Dietrich, Hanno Glimm, Mindaugas Andrulis, Christof von Kalle, Anthony D Ho, Thorsten Zenz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22621641     DOI： 10.1056/NEJMc1202124

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  85 in total

Review 1.  Emerging patterns of somatic mutations in cancer.

Authors:  Ian R Watson; Koichi Takahashi; P Andrew Futreal; Lynda Chin
Journal:  Nat Rev Genet       Date:  2013-09-11       Impact factor: 53.242

Review 2.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

Review 3.  Hairy cell leukemia: update and current therapeutic approach.

Authors:  Latif Salam; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

4.  Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.

Authors:  Prit Benny Malgulwar; Aruna Nambirajan; Pankaj Pathak; Mohammed Faruq; Vaishali Suri; Chitra Sarkar; Amandeep Jagdevan; Bhawani Shankar Sharma; Mehar Chand Sharma
Journal:  J Neurooncol       Date:  2017-05-12       Impact factor: 4.130

5.  Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

Authors:  Frederic Peyrade; Daniel Re; Clemence Ginet; Lauris Gastaud; Maryline Allegra; Robert Ballotti; Antoine Thyss; Thorsten Zenz; Patrick Auberger; Guillaume Robert
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

Review 6.  Microsurgical removal of craniopharyngioma: endoscopic and transcranial techniques for complication avoidance.

Authors:  Saira Alli; Semra Isik; James T Rutka
Journal:  J Neurooncol       Date:  2016-05-19       Impact factor: 4.130

Review 7.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

8.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

Review 9.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

Review 10.  Hairy cell leukemia: Past, present and future.

Authors:  Bartlomiej M Getta; Jae H Park; Martin S Tallman
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-21       Impact factor: 3.020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.